Lars Ekman, M.D., Ph.D.
Dr. Lars Ekman has 30 years of experience in senior executive, scientific and clinical functions. He has served as executive partner at Sofinnova Ventures since 2008, lending his extensive expertise in the life sciences industry to the investment team in driving new companies toward success.
Prior to joining Sofinnova Ventures, Lars was president of research and development at Elan. He is credited with advancing Elan’s drug discovery pipeline during his tenure, and under his leadership, the company received approval for four U.S. New Drug Applications, three European Marketing Approval Applications and five Investigational New Drug Applications. These efforts advanced Elan’s immunotherapeutic approach and brought to market three neuroscience products, including Tysabri for multiple sclerosis. Prior to joining Elan, Lars was executive vice president, research and development, at Schwarz Pharma AG, and before that, held a variety of senior scientific and clinical roles at Pharmacia (now Pfizer).
Lars is chairman of Amarin Corporation and Prothena Biosciences, executive chairman of Sophiris Bioscience, and a member of the board of directors of Ocera Therapeutics. He was co-founder and chief executive officer of Cebix, Inc. and previously served on the board of directors of InterMune (acquired by Roche) and Elan Pharmaceuticals (acquired by Perrigo).
Lars is a board-certified surgeon with a Ph.D. in experimental biology and an M.D. from the University of Gothenburg, Sweden.